Redwood City, CA – May 5, 2016 – Gynesonics, a women’s healthcare company focused on the
development of minimally invasive solutions for symptomatic uterine fibroids, today announced that
medical device executive Jiayu Chen, Ph.D., has been named Vice President of Engineering and Advanced
Technologies, effective immediately. Dr. Chen reports directly to President and CEO Christopher M.
Dr. Chen has more than 20 years of experience in the medical device industry with a particular emphasis on
product development from concept to commercialization, IP development and ultrasound technology
evaluation. Most recently, from 2013 to the present, Dr. Chen was a Chief Engineer at GE Ultrasound, a
division of GE Healthcare. In that role he provided technical leadership and guidance on innovation and
product strategies for research and development and clinical programs.
Prior to that, Dr. Chen spent 10 years (2003-2013) as Vice President of Engineering at Sunnyvale, CAbased U-Systems Inc, a manufacturer of ultrasound products for breast cancer applications that was
purchased by GE Healthcare in November 2012. Dr. Chen built and managed a highly-talented engineering
team and structured the company’s intellectual properties, among other duties.
Dr. Chen and his team at U-Systems Inc. delivered the first Premarket Approval (PMA) by the FDA of an
automated breast ultrasound system.
“Jiayu’s proven track record of innovation along with his strategic vision will add significant expertise to
our current and future technology platforms,” Owens said. “As we continue to thoughtfully scale the
organization, his depth of knowledge in ultrasound technology, leadership and drive for collaboration will
support new engineering development and clinical solutions, enhancing our product offerings, while
creating a foundation of excellence. We look forward to working with Jiayu and his contribution to the
continued success of the organization.”
Dr. Chen has a Masters of Science degree in mechanical engineering from Tsinghua University in China
and a doctorate in electrical engineering from Pennsylvania State University.
About Sonata System
The Sonata™ System, the next generation of Gynesonics’ technology platform (the previous generation
referred to as VizAblate), uses radiofrequency energy to ablate fibroids under intrauterine sonography
guidance. The Sonata™ System, including the SMART Targeting Guide, enables the operator to target
fibroids and optimize ablations within them. Sonata™ System’s design provides a straightforward,
transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is
designed to avoid the peritoneal cavity. In October 2014, Gynesonics announced FDA approval of the
SONATA IDE pivotal trial for their latest generation Sonata™ System.